Regional Market Access Lead - Central Eastern Europe, Middle East and Africa (CEEMEA) @ • Single point of contact for all CEEMEA market access issues and activities • Led preparation and submission of health technology assessment dossiers required by national authorities for inclusion of Shire portfolio into reimbursement schemes within CEEMEA • Led internal pricing approval and development of managed entry agreements within CEEMEA • Established and led a process for the collection and dissemination of information, data, insight and payer intelligence on specific CEEMEA and country market access requirements • Developed market access capabilities within CEEMEA • Support CEEMEA commercial team with guidance on market access strategy and policy From July 2015 to Present (6 months) Director of Market Access and Pricing @ • Developed and led implementation of pricing and market access strategy and tactics for Cubist antibiotic in order to minimise localisation efforts at affiliate level • Strategically guided the preparation and submission of health technology assessment dossiers required by national authorities for inclusion of Cubist product into reimbursement schemes • Developed hospital formulary packs to support access for Cubist antibiotic ensuring local adaptations are aligned to the Cubist International market access strategy • Provided specific input and direct support across all market access aspects for affiliate interactions, submissions and negotiations with payers and HTA bodies • Identified value evidence needs and led key initiatives to support value proposition for Cubist antibiotic From September 2014 to June 2015 (10 months) Senior Global Market Access Manager @ • Led the global pricing, market access and engagement strategy for a new product entering the obesity space, with significant focus on the US market • Developed a process to identify, understand, collate and communicate strategic payer insights to key stakeholders thereby optimising all brand global market access strategies • Led the planning of pricing and market access activities across the diabetes portfolio for the International Operations/emerging markets unit of Novo Nordisk, in particular by leading payer engagement activities • Established consistent global core competencies and job roles required in and across market access functions globally to increase the global market access capability of Novo Nordisk • Managed the global market access leadership body, Global Market Access Forum, in order to align global and local priorities and drive the influence of market access on senior management • Led the collaboration with Global Market Access and Global Public Affairs by supporting integration of public affairs planning with market access planning and providing the market access perspective for key public affairs initiatives From January 2013 to September 2014 (1 year 9 months) Senior Market Access Manager - Region Europe @ • Led a collaboration with the London School of Economics in EU5 highlighting the direct/indirect cost burden of diabetes and unmet needs for payers and policy makers to support policy change at EU and local level • Developed a market access planning process for European affiliates in order to enable affiliates to focus and prioritise on key challenges and to enable management to understand pricing and market access challenges • Initiated pan-European advisory board, chaired by the President of the European Association for the Study of Diabetes, in order to strengthen external relationships and gain payer insight resulting in securing endorsement of policy recommendations to drive change in diabetes • Provided recommendations to Novo Nordisk Region Europe senior management regarding affiliate requests for price changes in order to minimise the commercial risk from competitiion and payer/government induced price reductions/cuts • Supported European affiliates in implementing price and reimbursement strategies (incl. provide mock negotiation training and value communication training) From January 2010 to January 2013 (3 years 1 month) Senior Consultant @ • Provided recommendations on the pricing and market access potential of a new formulation entering the oncology space in EU5 and subsequently strategic recommendations for oncology franchise going forward to 2012 – achieving several follow-on opportunities within Swiss client • Provided recommendations for pricing and reimbursement (P&R) strategy across EU5 for a new hypertension drug using qualitative and quantitative pricing methods and subsequently produced value dossier containing P&R strategy • Assessed the commercial potential, key access and clinical development issues for a new anticoagulant in US and EU5 and provided recommendations to inform Phase III development • Synthesised insights and requirements from payer negotiations and recommended global best practice negotiation pathway and knowledge management tools in order to optimise future payer negotiation strategy • Led the market access workstream for the development of a global launch readiness framework for client preparing to launch two new products into the diabetes space From August 2007 to January 2010 (2 years 6 months) Healthcare Strategy Consultant @ UK • Analyzed potential impact of generic challenge in oncology market for Big Pharma client facing patent expiration. Provided strategic and tactical recommendations for channel management and pricing strategy • Assessed commercial potential for US Biotechnology firm initiating operations in Turkey in hepatitis B. Provided set of behavioral objectives to work towards in order to drive change in line with client positioning From January 2007 to June 2007 (6 months) MBA Summer Associate @ • Interviewed and persuaded senior Novartis managers and senior associates at European industry bodies on issues of Market Access Delays, Health Technology Assessment/Relative Effectiveness and Parallel Trade to create the Novartis corporate policy position • Analyzed reimbursement delay data to produce compelling case studies highlighting countries with best and worse practice From June 2006 to August 2006 (3 months) PR Executive @ • Managed 11 public relations (PR) programs across oncology and virology portfolios ensuring PR plans delivered in line with marketing objectives. Contributions led to receiving ‘Team of the Year’ internal award • Identified the need for a UK advocacy group for hepatitis C in line with Roche key messages. Persuaded marketing team to invest in the advocacy group which was critical for positive recommendation by National Institute for Clinical Excellence • Devised media strategy for a campaign to highlight the issue of 'postcode prescribing' in cancer, the consequences of which revolutionised cancer management in the UK • Responsible for issues management surrounding launch of Avastin in the UK, securing positive national media coverage and minimizing focus of coverage on cost • Provided strategic counsel to marketing teams across HIV portfolio regarding supply and usage From 2003 to 2005 (2 years) Senior Account Executive @ • Created global strategy for managing issues surrounding new product launch for Eli Lilly • Pitched to PR industry publications and organized events in corporate MS&L PR role. Received global internal MS&L award for increasing profile of MS&L and achieving consistent coverage. • Managed day-to-day workflow for client team From 2002 to 2003 (1 year) Account Executive @ Graduate training position in health care team. Major responsibilities: • Managed media relations for UK launch of diabetes therapy for Novartis Pharmaceuticals • Media liaison for Roche Pharmaceuticals - Basel From September 2000 to May 2002 (1 year 9 months) Pre-Registation Pharmacist @ • Designed six month project analysing effect of excipient properties on absorption profile of phase II compound to make recommendations to Drug Development team • Completed six months training at St George’s Hospital London in order to register with the Royal Pharmaceutical Society of Great Britain (MRPharmS) From September 1999 to June 2000 (10 months)

MBA, Business @ London Business School From 2005 to 2007 MBA, Focus on health care @ University of California, Berkeley, Haas School of Business From 2006 to 2007 BPharm, Pharmacy @ University of Nottingham From 1996 to 1999 Novo Nordisk Global Marketing - Emerging Leaders Programme Helen Stoop is skilled in: Pharmaceutical Industry, Oncology, Market Access, Pricing, Diabetes, Value Communication, Stakeholder Engagement, Strategic Planning, Project Management, Health Economics, Healthcare, Medical Devices, Regulatory Affairs, Biotechnology, Pharmacovigilance